Bluejay Diagnostics, Inc. 8-K

What Happened

• Bluejay Diagnostics, Inc. announced a private placement under a Securities Purchase Agreement dated March 14, 2026 that closed on March 17, 2026. The company issued 62,500 shares of common stock at $2.00 per share, generating $125,000 in gross proceeds.
• Purchasers were five insiders: Neil Dey (President & CEO, board member), Donald Chase (Chair of the Board), Svetlana Dey, Douglas Wurth and Fred Zeidman (each a director). Each purchased 12,500 shares for their own accounts.

Key Details

• 62,500 shares issued at $2.00 per share = $125,000 gross proceeds.
• Securities Purchase Agreement dated March 14, 2026; closing on March 17, 2026.
• Sale was unregistered and conducted pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D; purchasers represented they are accredited investors.
• The company did not grant registration rights for the shares; the offering involved no general solicitation.

Why It Matters

• The company received $125,000 in immediate financing from insiders, which provides cash but does not come with registration or resale rights for the shares. For investors, key takeaways are the insider participation (management and board members bought shares) and the unregistered nature of the sale, which affects liquidity of these shares. The filing is informational about the transaction terms; it does not state use of proceeds or changes to overall share count beyond the issuance.